BROOMALL, PA — Drummond Scientific Company has entered into an exclusive licensing agreement with Tufts University to bring an innovative plasma separation technology to market. Developed by Professor Charlie Mace and the Mace Lab at Tufts, this paper-based solution enables rapid collection and separation of plasma from a single drop of blood, eliminating the need for centrifuges or traditional phlebotomy.
Recognizing the potential impact of this technology, Drummond sponsored the initial research, which now promises to advance diagnostic testing, particularly in point-of-care (POC), at-home, and remote settings. Patients can collect plasma samples via a simple fingerstick, paving the way for faster diagnosis and treatment in regions with limited access to laboratory equipment.
“Our mission is to develop affordable, patient-centric technologies that improve access to healthcare,” said Dr. Charlie Mace, Associate Professor of Chemistry at Tufts University. “This partnership with Drummond empowers us to translate groundbreaking research into real-world point-of-care diagnostic solutions.”
The paper-based devices are geared toward use in resource-limited areas and among patients with restricted mobility. Samples can be mailed to laboratories for analysis, making this technology conducive to global healthcare initiatives and emergency medical situations.
Drummond Scientific President and CEO Christopher Strohsahl expressed enthusiasm for the innovation, stating, “By streamlining plasma collection, we’re making diagnostic testing faster, more efficient, and accessible where it’s needed most.”
Looking forward, Drummond plans to make the technology widely available, expanding healthcare access and advancing diagnostic innovations for underserved populations worldwide. This breakthrough represents a significant step in improving patient care and enabling timely medical interventions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.